In February of 2021, Emmaus Life Sciences and Kainos Medicine entered into an agreement to jointly develop Kainos’ patented IRAK4 inhibitor (KM10544). IRAK4 is a serine-threonine protein kinase known to be present and active in the occurrence of certain immunity responses, inflammation disorders, and various cancers. Under the terms of this agreement, Kainos will study […] The post BioSci Deal of the Month – Kainos Medicines & Emmaus Life Sciences appeared first on Evaluate.
